AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

Rhea-AI Summary

AC Immune (NASDAQ: ACIU) announced five data presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD^TM) from March 15-20, 2022, showcasing its focus on neurodegenerative diseases. Prof. Andrea Pfeifer, CEO, highlighted a significant milestone: the first in-human study of the ACI-12589 a-syn PET tracer. This research aims to enhance disease detection and prevention strategies through precision medicine. These presentations underline the company's commitment to advancing treatments for neurodegenerative diseases, potentially impacting future market performance.

Positive

• First in-human study for ACI-12589, a novel a-syn PET tracer, indicates progress in precision medicine.
• Five presentations at AD/PD 2022 demonstrate commitment to research in neurodegenerative diseases.
• Strong partnerships with leading pharmaceutical companies offer substantial non-dilutive funding.

Negative

• None.

Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD^TM)

AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies

LAUSANNE, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that five new data presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD^TM), taking place in Barcelona, Spain, and virtually on March 15–20, 2022. In addition, Prof. Johannes Streffer, Chief Medical Officer of AC Immune SA, will join an expert panel to discuss novel insights, challenges and solutions for innovative approaches in AD and PD therapeutics.

Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune will present new data supporting its precision medicine approach in neurodegenerative diseases (NDD), notably the very first ever in-human study for an a-syn PET Tracer, with our first-in-class ACI-12589. By pairing our diagnostics with therapeutics targeting proteinopathies, we aim to shift the treatment paradigm towards better disease detection and prevention in the NDD patient population.”

AC Immune presentations at AD/PD^TM 2022

Translational drug discovery in PD/LBD Phase I-III – Recent updates
Date: Thu, 17.03.2022 | 03:50 PM - 04:50 PM | Onsite Plenary: 115-117
Panelist: Forum discussion with Prof. Johannes Streffer (AC Immune)

ACI-12589 alpha-synuclein imaging agent

Discovery of [18F] ACI-12589, a novel and promising PET-tracer for alpha-synuclein
Date: Fri, 18.03.2022 | 10:25 AM - 10:40 AM | Room Onsite: 114
Presenter: Oral presentation by Francesca Capotosti, Ph.D. (AC Immune)

Initial scans using [18F] ACI-12589, a novel PET-tracer for alpha-synuclein
Date: Fri, 18.03.2022 | 06:45 PM - 07:00 PM | Room Onsite: 114
Presenter: Oral presentation by Prof. Ruben Smith (Skåne University Hospital, Lund, Sweden)

ACI-24 anti-Abeta vaccine

An optimized amyloid beta (abeta) vaccine that safely drives immunity to the key pathological species of Alzheimer’s disease (AD)
Date: Fri, 18.03.2022 | 04:15 PM - 04:30 PM| Room Onsite: 112
Presenter: Oral presentation by Marija Vukicevic, Ph.D. (AC Immune)

TDP-43 therapeutics & diagnostics

TDP-43 immunotherapy decreases neuropathology and confers neuroprotection through microglial engagement in mouse models of ALS/FTD
Date: Fri, 18.03.2022 | 10:25 AM - 10:40 AM | Room Onsite: 113
Presenter: Oral presentation by Tariq Afroz, Ph.D. (AC Immune)

TDP-43 and C9ORF72-related diseases 2: optimization of PET Tracers for TDP-43 proteinopathies
Date: Available online from 15.03.2022
Presenter: On demand presentation by Tamara Seredenina, Ph.D. (AC Immune)

About AC Immune SA
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen^® and Morphomer^®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

SupraAntigen^® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer^® is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

For further information, please contact:

Media Relations Saoyuth Nidh AC Immune Phone: +41 21 345 91 34 Email: saoyuth.nidh@acimmune.com	Investor Relations Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com
U.S. Media Shani Lewis LaVoieHealthScience Phone: +1 609 516 5761 Email: slewis@lavoiehealthscience.com	U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com

Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

FAQ

What is the focus of AC Immune's presentations at the AD/PD conference?

AC Immune's presentations focus on neurodegenerative diseases, showcasing advancements in precision medicine and novel PET tracers.

What is the significance of the ACI-12589 study for AC Immune?

The ACI-12589 study marks the first in-human use of this a-syn PET tracer, aiming to improve disease detection and treatment strategies.

When is the AD/PD conference taking place?

The AD/PD conference is scheduled from March 15-20, 2022.

What potential impact could the data presented have on AC Immune's stock?

Positive data could enhance AC Immune's reputation in neurodegenerative disease treatment and potentially boost investor confidence.

How many presentations will AC Immune deliver at the AD/PD conference?

AC Immune will deliver five presentations at the AD/PD conference.